Cell death associated with genetic prodrug activation therapy of colorectal cancer

Stephen Todryk, Alan Melcher, Graham Bottley, Michael Gough, Richard Geoffrey Vile

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Genetic prodrug activation therapy (GPAT) is a form of cancer gene therapy that has potential use against tumours such as colorectal malignancy. The characterization of such therapies using laboratory models provides a basis for clinical trials. In this study the gene encoding Herpes Simplex Virus thymidine kinase (HSVtk) was delivered to colorectal tumour cells using an Adenoviral (Ad) vector in vitro. In this way the cells were made susceptible to killing with the prodrug ganciclovir to various degrees depending on cell infectability with Ad. Bystander killing effect appeared minimal both in vitro and when transduced cells were injected in vivo. Mechanisms of cell death, measured in vitro using anti-BrDU (DNA-break labelling) and propidium iodide staining variously showed a combination of apoptosis in the G1 cell cycle phase and late apoptotic or necrotic sub-G1 DNA fragmentation, depending on the tumour cell line. These findings suggest that gene therapy of colorectal cancer by GPAT gives rise to therapeutic forms of direct cell death, but requires improvements in transduction, and possibly immune augmentation.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalCancer Letters
Volume174
Issue number1
DOIs
StatePublished - Dec 10 2001

Fingerprint

Prodrugs
Colorectal Neoplasms
Cell Death
Genetic Therapy
Bystander Effect
Ganciclovir
DNA Breaks
Thymidine Kinase
Propidium
Neoplasm Genes
DNA Fragmentation
Simplexvirus
Therapeutics
Tumor Cell Line
Neoplasms
Cell Cycle
Clinical Trials
Apoptosis
Staining and Labeling
Genes

Keywords

  • Cell death
  • Colorectal cancer
  • Gene therapy
  • Genetic prodrug activation therapy
  • Immunity

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Cell death associated with genetic prodrug activation therapy of colorectal cancer. / Todryk, Stephen; Melcher, Alan; Bottley, Graham; Gough, Michael; Vile, Richard Geoffrey.

In: Cancer Letters, Vol. 174, No. 1, 10.12.2001, p. 25-33.

Research output: Contribution to journalArticle

Todryk, Stephen ; Melcher, Alan ; Bottley, Graham ; Gough, Michael ; Vile, Richard Geoffrey. / Cell death associated with genetic prodrug activation therapy of colorectal cancer. In: Cancer Letters. 2001 ; Vol. 174, No. 1. pp. 25-33.
@article{1a714f09f0ca41c290e86f03e008d60a,
title = "Cell death associated with genetic prodrug activation therapy of colorectal cancer",
abstract = "Genetic prodrug activation therapy (GPAT) is a form of cancer gene therapy that has potential use against tumours such as colorectal malignancy. The characterization of such therapies using laboratory models provides a basis for clinical trials. In this study the gene encoding Herpes Simplex Virus thymidine kinase (HSVtk) was delivered to colorectal tumour cells using an Adenoviral (Ad) vector in vitro. In this way the cells were made susceptible to killing with the prodrug ganciclovir to various degrees depending on cell infectability with Ad. Bystander killing effect appeared minimal both in vitro and when transduced cells were injected in vivo. Mechanisms of cell death, measured in vitro using anti-BrDU (DNA-break labelling) and propidium iodide staining variously showed a combination of apoptosis in the G1 cell cycle phase and late apoptotic or necrotic sub-G1 DNA fragmentation, depending on the tumour cell line. These findings suggest that gene therapy of colorectal cancer by GPAT gives rise to therapeutic forms of direct cell death, but requires improvements in transduction, and possibly immune augmentation.",
keywords = "Cell death, Colorectal cancer, Gene therapy, Genetic prodrug activation therapy, Immunity",
author = "Stephen Todryk and Alan Melcher and Graham Bottley and Michael Gough and Vile, {Richard Geoffrey}",
year = "2001",
month = "12",
day = "10",
doi = "10.1016/S0304-3835(01)00679-6",
language = "English (US)",
volume = "174",
pages = "25--33",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Cell death associated with genetic prodrug activation therapy of colorectal cancer

AU - Todryk, Stephen

AU - Melcher, Alan

AU - Bottley, Graham

AU - Gough, Michael

AU - Vile, Richard Geoffrey

PY - 2001/12/10

Y1 - 2001/12/10

N2 - Genetic prodrug activation therapy (GPAT) is a form of cancer gene therapy that has potential use against tumours such as colorectal malignancy. The characterization of such therapies using laboratory models provides a basis for clinical trials. In this study the gene encoding Herpes Simplex Virus thymidine kinase (HSVtk) was delivered to colorectal tumour cells using an Adenoviral (Ad) vector in vitro. In this way the cells were made susceptible to killing with the prodrug ganciclovir to various degrees depending on cell infectability with Ad. Bystander killing effect appeared minimal both in vitro and when transduced cells were injected in vivo. Mechanisms of cell death, measured in vitro using anti-BrDU (DNA-break labelling) and propidium iodide staining variously showed a combination of apoptosis in the G1 cell cycle phase and late apoptotic or necrotic sub-G1 DNA fragmentation, depending on the tumour cell line. These findings suggest that gene therapy of colorectal cancer by GPAT gives rise to therapeutic forms of direct cell death, but requires improvements in transduction, and possibly immune augmentation.

AB - Genetic prodrug activation therapy (GPAT) is a form of cancer gene therapy that has potential use against tumours such as colorectal malignancy. The characterization of such therapies using laboratory models provides a basis for clinical trials. In this study the gene encoding Herpes Simplex Virus thymidine kinase (HSVtk) was delivered to colorectal tumour cells using an Adenoviral (Ad) vector in vitro. In this way the cells were made susceptible to killing with the prodrug ganciclovir to various degrees depending on cell infectability with Ad. Bystander killing effect appeared minimal both in vitro and when transduced cells were injected in vivo. Mechanisms of cell death, measured in vitro using anti-BrDU (DNA-break labelling) and propidium iodide staining variously showed a combination of apoptosis in the G1 cell cycle phase and late apoptotic or necrotic sub-G1 DNA fragmentation, depending on the tumour cell line. These findings suggest that gene therapy of colorectal cancer by GPAT gives rise to therapeutic forms of direct cell death, but requires improvements in transduction, and possibly immune augmentation.

KW - Cell death

KW - Colorectal cancer

KW - Gene therapy

KW - Genetic prodrug activation therapy

KW - Immunity

UR - http://www.scopus.com/inward/record.url?scp=0035841950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035841950&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(01)00679-6

DO - 10.1016/S0304-3835(01)00679-6

M3 - Article

C2 - 11675149

AN - SCOPUS:0035841950

VL - 174

SP - 25

EP - 33

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -